Ritu Baral
Stock Analyst at TD Cowen
(0.98)
# 3,695
Out of 4,876 analysts
36
Total ratings
40%
Success rate
-13.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $20.62 | +113.39% | 1 | Feb 5, 2025 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $9 | $9.28 | -3.02% | 6 | Nov 21, 2024 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.90 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.08 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $29.83 | +161.48% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $318.25 | +16.58% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $101.74 | -3.68% | 3 | Aug 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $299.51 | +30.21% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $8.70 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $17.23 | +915.67% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $21 | $22.21 | -5.45% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.36 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.40 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.25 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $23.29 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.00 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.30 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.62 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $803.95 | - | 2 | Jan 12, 2018 |
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $20.62
Upside: +113.39%
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $9.28
Upside: -3.02%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.90
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.08
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $29.83
Upside: +161.48%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $318.25
Upside: +16.58%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $101.74
Upside: -3.68%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $299.51
Upside: +30.21%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $8.70
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $17.23
Upside: +915.67%
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $22.21
Upside: -5.45%
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.36
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.40
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.25
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $23.29
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.00
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.30
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.62
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $803.95
Upside: -